ICU Medical, Inc. (ICUI)
| Market Cap | 4.39B +39.8% |
| Revenue (ttm) | 2.18B -5.9% |
| Net Income | 60.33M |
| EPS | 2.40 |
| Shares Out | 25.01M |
| PE Ratio | 73.33 |
| Forward PE | 50.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,377 |
| Open | 173.90 |
| Previous Close | 172.11 |
| Day's Range | 172.55 - 179.66 |
| 52-Week Range | 113.37 - 192.85 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 194.25 (+10.53%) |
| Earnings Date | Nov 5, 2026 |
About ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinf... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ICUI stock is "Buy." The 12-month stock price target is $194.25, which is an increase of 10.53% from the latest price.
News
ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London
SAN CLEMENTE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company...
ICU Medical price target raised to $189 from $187 at KeyBanc
KeyBanc raised the firm’s price target on ICU Medical (ICUI) to $189 from $187 on lower net debt, while keeping an Overweight rating on the shares. The firm viewed Q3…
ICU Medical price target raised to $200 from $195 at Piper Sandler
Piper Sandler raised the firm’s price target on ICU Medical (ICUI) to $200 from $195 and keeps an Overweight rating on the shares. The firm notes the company reported Q3…
ICU Medical reports Q3 EPS $2.44, consensus $2.15
Reports Q3 revenue $560.44M, consensus $553.95M. Vivek Jain, ICU Medical’s (ICUI) Chief Executive Officer, said, “Third quarter results were ahead of our expectations for Infusion Systems and generall...
ICU Medical backs FY26 adjusted EPS view $8.60-$9.00 from $8.75
Backs FY26 adjusted EBITDA view $415M-$435M. The company said, “The Company is reaffirming its full year 2026 guidance but expects to end the fiscal year towards the higher end of…
ICU Medical Earnings Call Transcript: Q3 2026
Q3 revenue and adjusted earnings grew, with record Consumables and Infusion Systems sales and improving margins. FY26 EBITDA and EPS are expected toward the high end of guidance, while logistics disruption, tariffs, and macro volatility remain key considerations.
ICU Medical Earnings release: Q3 2026
ICU Medical released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
ICU Medical Quarterly report: Q3 2026
ICU Medical has published its Q3 2026 quarterly earnings report on November 5, 2026.
ICU Medical Slides: Q3 2026
ICU Medical has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range
SAN CLEMENTE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial res...
ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call
SAN CLEMENTE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of ...
ICU Medical Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Stable hospital demand and a coherent portfolio strategy support ongoing growth, with pump upgrades and competitive wins as key drivers. Tariffs remain the main macro risk, while margin improvement and disciplined capital allocation are prioritized.
ICU Medical Transcript: Wells Fargo 21st Annual Healthcare Conference
Stable demand and hospital admissions support current growth, with IV systems and consumables showing reliable performance. Portfolio strategy emphasizes capital efficiency, while pump upgrades and regulatory filings are progressing. Margin improvement and shareholder returns are key financial priorities.
ICU Medical to Participate in Upcoming Investor Conferences
SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its particip...
ICU Medical price target raised to $200 from $180 at Raymond James
Raymond James raised the firm’s price target on ICU Medical (ICUI) to $200 from $180 and keeps a Strong Buy rating on the shares.
ICU Medical price target raised to $187 from $165 at Needham
Needham analyst Mike Matson raised the firm’s price target on ICU Medical (ICUI) to $187 from $165 and keeps a Buy rating on the shares. The firm cites higher earnings…
ICU Medical price target raised to $200 from $170 at BTIG
BTIG raised the firm’s price target on ICU Medical (ICUI) to $200 from $170 and keeps a Buy rating on the shares. ICU Medical delivered a strong Q2 with revenue,…
ICU Medical reports Q2 adjusted EPS $2.37, consensus $1.91
Reports Q2 revenue $551.68M, consensus $534.21M. Vivek Jain, ICU Medical’s (ICUI) Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and general...
ICU Medical raises FY26 adjusted EPS view to $9.60-$8.90 from $7.75-$8.45
Consensus $8.16. Raises FY26 adjusted EBITDA view to $415M-$435M from $400M-$430M. The company said, “For Fiscal Year 2026 the Company is updating its estimates of GAAP net income from a…
ICU Medical Earnings Call Transcript: Q2 2026
Q2 saw 6% organic revenue growth, record sales in consumables and infusion systems, and improved margins. Guidance for full-year adjusted EBITDA and EPS was raised, with strong free cash flow supporting debt reduction and a focus on margin expansion despite ongoing currency and tariff headwinds.
ICU Medical Earnings release: Q2 2026
ICU Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
ICU Medical Slides: Q2 2026
ICU Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
ICU Medical Quarterly report: Q2 2026
ICU Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial res...
ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call
SAN CLEMENTE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of ...